Papers - MORITAKE Hiroshi
-
MORITAKE Hiroshi
Rinsho Ketsueki 61 ( 6 ) 665 - 672 2020
Authorship：Lead author, Corresponding author Language：Japanese Publishing type：Research paper (scientific journal) Publisher：The Japanese Society of Hematology
In Japan, acute myeloid leukemia (AML) accounts for approximately 25% of all pediatric leukemias, with approximately 150 cases of newly diagnosed AML occurring annually. Approximately 10% of patients have primary induction failure and 30% of patients, who initially achieve remission in primary treatments, subsequently relapse. Novel treatment modalities need to be developed to further improve the prognosis of pediatric AML patients. AML is a heterogeneous genetic disease characterized by changes in the genome of hematopoietic progenitor cells. Recent studies that have made progress in research related to the pathogenesis of AML have suggested that genotype-specific treatment strategies are associated with increased efficacy. Potential new therapeutic alternatives for pediatric AML include: tyrosine kinase inhibitors, monoclonal or bispecific T-cell engager antibodies, chimeric antigen receptor T-cell therapy, and metabolic agents. This review highlights the current landscape of novel therapeutic approaches for childhood AML, including the results of both preclinical and clinical trials, as well as introducing the results of several preceding adult clinical studies, which could potentially be translated into pediatric AML patients.
-
急速に片側腎の機能低下を認めたシスチン尿症の1例 Reviewed
黒木 純，此元 隆雄, 今村 秀明，中原 梢, 寺田 直樹, 上村 敏雄，賀本 敏行，盛武 浩
日本小児腎不全学会雑誌 40 297 - 300 2020
Authorship：Lead author, Last author Language：Japanese Publishing type：Research paper (scientific journal)
-
乳幼児早期に経後腹膜到達法による腹腔鏡下腎摘出を行った片側多嚢胞性異形成腎の１例 Reviewed
長友 美佳, 此元 隆雄, 黒木 純, 今村 秀明, 中原 梢, 寺田 直樹, 上村 敏雄, 賀本 敏行, 盛武 浩
日本小児腎不全学会雑誌 40 301 - 304 2020
Authorship：Lead author, Last author Language：Japanese Publishing type：Case report
-
Moritake Hiroshi
The Japanese Journal of Pediatric Hematology / Oncology 57 ( 3 ) 240 - 250 2020
Authorship：Lead author, Corresponding author Language：Japanese Publishing type：Research paper (scientific journal) Publisher：The Japanese Society of Pediatric Hematology / Oncology
Acute myeloid leukemia (AML) accounts for approximately 25% of pediatric leukemia cases, with approximately 180 patients newly diagnosed each year in Japan. In general, AML is classified into three groups [acute promyelocytic leukemia (APL), myeloid leukemia associated with Down syndrome (ML-DS), and others] and is treated with different treatment strategies. Retinoic acid with conventional chemotherapy leads to a safe and promising outcome in patients with APL. Recently, arsenic trioxide and gemtuzumab ozogamicin have been expected to reduce late complications and further improve treatment outcomes. Reduced-intensity chemotherapy is effective for patients with ML-DS; however, the prognoses of relapsed and refractory patients are dismal. Optimization of the classification of patients with ML-DS into several groups is desired; thus, the measurement of minimal residual disease by flow cytometry and the detection of <i>GATA1</i> mutations is expected. For patients with other types of AML, they may be further classified into three groups on the basis of risk stratification according to chromosome and genetic analyses and chemosensitivity to induction therapy. However, the prognosis of patients with a refractory or relapsed disease remains a serious problem that should be solved. A novel therapeutic approach that includes the use of FLT3 inhibitors, which has recently been approved in Japan for adult patients with relapsed and refractory AML bearing <i>FLT3</i>-ITD, will be necessary to improve their prognosis.
-
乳児期早期に腎摘出を行った多嚢胞性異形成腎の1例 Reviewed
長友 美佳, 黒木 純, 今村 秀明, 此元 隆雄, 盛 武浩, 中原 梢, 寺田 直樹, 上村 敏雄, 賀本 敏行
日本小児腎臓病学会雑誌 32 ( 2 ) 157 - 158 2019.11
Publishing type：Case report
-
Saito Y, Sawa D, Kinoshita M, Yamada A, Kamimura S, Suekane A, Ogoh H, Matsuo H, Adachi S, Taga T, Tomizawa D, Osato M, Soga T, Morishita K, Moritake H
Haematologica 105 ( 8 ) 2118 - 2129 2019.10
Authorship：Corresponding author Language：English Publishing type：Research paper (scientific journal) Publisher：Haematologica
Metabolic reprogramming of leukemia cells is important for survival, proliferation, and drug resistance under conditions of metabolic stress in the bone marrow. Deregulation of cellular metabolism, leading to development of leukemia, occurs through abnormally high expression of transcription factors such as MYC and Ecotropic Virus Integration site 1 protein homolog (EVI1). Overexpression of EVI1 in adults and children with mixed lineage leukemia-rearrangement acute myeloid leukemia (MLL-r AML) has a very poor prognosis. To identify a metabolic inhibitor for EVI1-induced metabolic reprogramming in MLL-r AML, we used an XFp extracellular flux analyzer to examine metabolic changes during leukemia development in mouse models of AML expressing MLL-AF9 and Evi1 (Evi1/MF9). Oxidative phosphorylation (OXPHOS) in Evi1/MF9 AML cells accelerated prior to activation of glycolysis, with a higher dependency on glutamine as an energy source. Furthermore, EVI1 played a role in glycolysis as well as driving production of metabolites in the tricarboxylic acid cycle. L-asparaginase (L-asp) exacerbated growth inhibition induced by glutamine starvation and suppressed OXPHOS and proliferation of Evi1/MF9 both in vitro and in vivo; high sensitivity to L-asp was caused by low expression of asparagine synthetase (ASNS) and L-asp-induced suppression of glutamine metabolism. In addition, samples from patients with EVI1+MF9 showed low ASNS expression, suggesting that it is a sensitive marker of L-asp treatment. Clarification of metabolic reprogramming in EVI1+ leukemia cells may aid development of treatments for EVI1+MF9 refractory leukemia.
-
学童期に発症した腸重積症の1例 Reviewed
押方 真, 山下 尚人, 近藤 恭平, 盛武 浩, 鈴東 昌也
日本小児科学会雑誌 123 ( 10 ) 1586 - 1586 2019.10
Publishing type：Case report
-
食道穿孔をきたしたリチウム電池誤飲
原尾 拓朗, 木許 恭宏, 盛武 浩, 鈴東 昌也, 井手 慎介
日本小児科学会雑誌 123 ( 10 ) 1586 - 1586 2019.10
Publishing type：Research paper (scientific journal)
-
横紋筋融解を契機に判明したCPT2欠損症の兄弟例 Reviewed
宇藤山 麻衣子, 麻田 智子, 松山 美靜代, 盛武 浩, 澤田 浩武
日本小児科学会雑誌 123 ( 10 ) 1587 - 1587 2019.10
Publishing type：Case report
-
インフルエンザ罹患を契機に顕在化した遅発型Leigh症候群の1例 Reviewed
横山 亮平 ,木許 恭宏, 谷口 英里奈, 池田 俊郎, 盛武 浩
日本小児科学会雑誌 123 ( 10 ) 1587 - 1587 2019.10
Publishing type：Case report
-
胎児期発症拡張型心筋症の孤発例 Reviewed
押方 真, 山下 尚人, 近藤 恭平, 盛武 浩, 山口 智子, 紀 愛美, 山下 理絵, 児玉 由紀
日本小児科学会雑誌 123 ( 10 ) 1588 - 1588 2019.10
Publishing type：Research paper (scientific journal)
-
超大量フェノバルビタールとケトン食療法に加えペランパネルが奏功したAERRPS Reviewed
黒木 亜津子, 木許 恭宏, 谷口 英里奈, 池田 俊郎, 盛武 浩
日本小児科学会雑誌 123 ( 10 ) 1588 - 1588 2019.10
Publishing type：Research paper (scientific journal)
-
ヌシネルセンナトリウム髄腔内投与により呼吸・運動機能の改善を認めた脊髄性筋萎縮症I型 Reviewed
原尾 拓朗, 木許 恭宏, 谷口 英里奈, 池田 俊郎, 盛武 浩
日本小児科学会雑誌 123 ( 10 ) 1588 - 1589 2019.10
Publishing type：Research paper (scientific journal)
-
HHV-6感染を契機とした急性壊死性脳症の1例 Reviewed
横山 亮平, 木許 恭宏, 谷口 英里奈, 池田 俊郎, 盛武 浩
日本小児科学会雑誌 123 ( 10 ) 1589 - 1589 2019.10
Publishing type：Case report
-
リツキシマブ投与を行った難治性ネフローゼ症候群の検討 Reviewed
黒木 純, 今村 秀明, 此元 隆雄, 盛武 浩
日本小児科学会雑誌 123 ( 10 ) 1589 - 1589 2019.10
Publishing type：Research paper (scientific journal)
-
JPLSGにおける急性骨髄性白血病治療の歴史と現状、そして克服すべき課題について Reviewed
盛武 浩
日本小児血液・がん学会雑誌 56 ( 4 ) 171 - 171 2019.10
Publishing type：Research paper (scientific journal)
-
チオ硫酸ナトリウム使用によりシスプラチン誘発性聴力障害の進行が抑制された髄芽腫 Reviewed
原尾 拓朗, 山田 愛, 木下 真理子, 齋藤 祐介, 上村 幸代, 盛武 浩
日本小児血液・がん学会雑誌 56 ( 4 ) 341 - 341 2019.10
Publishing type：Research paper (scientific journal)
-
市中型MRSA敗血症を併発した細菌性気管炎の1例 Reviewed
原田 雅子, 入佐 浩史, 黒木 純, 山下 尚人, 山元 綾子, 木許 恭宏, 今村 秀明, 盛武 浩, 宮原 史和
日本小児呼吸器学会雑誌 30 126 - 126 2019.9
Publishing type：Case report
-
抗MOG抗体陽性のtumefactive demyelinating lesion(TDL)の1例 Reviewed
木許 恭宏, 原尾 拓朗, 谷口 英里奈, 池田 俊郎, 盛武 浩
脳と発達 51 ( 5 ) 332 - 332 2019.9
Publishing type：Case report
-
パゾパニブで延命効果を認めた難治性Ewing肉腫 Reviewed
横山 亮平, 山田 愛, 木下 真理子, 澤 大介, 齋藤 祐介, 上村 幸代, 盛武 浩
日本小児血液・がん学会雑誌 56 ( 2 ) 272 - 272 2019.9
Publishing type：Research paper (scientific journal)